MedTrace Logo

CORAL XT - Open-label Extension Trial of the CORAL Trial

NCT02031432 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 76

Last updated 2021-07-15

Study results available
· View outcomes & findings →

Summary

The purpose of this trial was to find out how well cebranopadol is tolerated and how often, and which, adverse reactions occur when it is taken every day for a longer period of time. In addition, information was collected how cebranopadol affects pain and well-being in patients suffering from cancer-related pain.

Conditions

Interventions

DRUG

Cebranopadol

Film-coated tablet; strengths: 200, 400, or 600 µg

Sponsors & Collaborators

  • Tris Pharma, Inc.

    lead INDUSTRY

Principal Investigators

  • Director Clinical Trials · Grünenthal GmbH

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-12-18
Primary Completion
2016-04-30
Completion
2016-05-03

Countries

  • Austria
  • Belgium
  • Bulgaria
  • Denmark
  • Germany
  • Hungary
  • Poland
  • Romania
  • Serbia
  • Slovakia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02031432 on ClinicalTrials.gov